Cancer-related inflammation as predicting tool for treatment outcome in locally advanced and metastatic non-small cell lung cancer

Badovinac, Sonja; Koršić, Marta; Muršić, Davorka; Samaržija, Miroslav; Čučević, Branka; Roglić, M; Jakopović, Marko

doi:10.21037/jtd.2016.05.56

Cited by 5 publications

(11 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, NSCLC patients with preoperative thrombocytosis, platelet-to-lymphocyte ratio (PLR), neutrophil/lymphocyte ratio and prognostic nutritional index showed a significantly shorter disease-free survival (DFS) and OS (5)(6)(7). Similarly, elevated platelets count, C-reactive protein and high fibrinogen level were demonstrated as independent poor prognostic factors also in patients with advanced NSCLC (8,9).…”

Section: Introductionmentioning

confidence: 99%

Pre-treatment systemic immune-inflammation represents a prognostic factor in patients with advanced non-small cell lung cancer

Berardi¹,

Santoni²,

Rinaldi³

et al. 2019

Ann. Transl. Med.

View full text Add to dashboard Cite

Background: Inflammation plays an important role in pathogenesis, development and progression of lung cancer. The aim of the study is to assess the prognostic role of Systemic Immune-Inflammation Index (SII), obtained by analyzing the neutrophil, lymphocyte and platelet counts, and to design prognostic models for patients receiving first-line chemo-or targeted therapy for advanced non-small cell lung cancer (NSCLC). Methods:We conducted an analysis on 311 patients with advanced NSCLC, treated with first line chemoor targeted therapy till June 2015 at our Institution. Patients were stratified in two groups with SII ≥1,270 (Group A) vs. SII <1,270 (Group B). Progression free survival (PFS) and overall survival (OS) were estimated using Kaplan-Meier method. The best SII cutoff was identified by X-tiles program. A Cox regression model was carried out for univariate and multivariate analyses.Results: At baseline, 179 patients had SII ≥1,270 (Group A), whilst 132 had lower SII (Group B). The median OS was 12.4 months in Group A and 21.7 months in Group B (P<0.001), whilst the median PFS was 3.3 and 5.2 months, respectively (P=0.029). At multivariate analysis, male gender, ECOG-PS ≥2 and SII >1,270 were predictors of worst OS, whilst IV tumor stage was only slightly significant (P=0.08). Otherwise, only wild-type EGFR status and SII ≥1,270 were independent prognostic factors for worst PFS.Conclusions: Pre-treatment SII is an independent prognostic factor for patients with advanced NSCLC treated with first-line therapies.

show abstract

Section: Introductionmentioning

confidence: 99%

Pre-treatment systemic immune-inflammation represents a prognostic factor in patients with advanced non-small cell lung cancer

Berardi¹,

Santoni²,

Rinaldi³

et al. 2019

Ann. Transl. Med.

View full text Add to dashboard Cite

show abstract

“…Fbg may promote stable adhesion among tumor cells, platelets, and endothelial cells, [3,7,20,21] thereby further protecting the tumor cells from the impact of the immune system, enhancing the ability of cell establishment, deep infiltration, and metastasis. [4,22] Therefore, in our research and early studies, we found the later the N, M, and CS were, the higher the average levels of plasma Fbg were. [19]…”

Section: Discussionmentioning

confidence: 55%

“…Hyperfibrinogenemia can exist in many patients with malignant tumors including NSCLC and SCLC, which suggests a poor prognosis. [4,5,7,10,19] Fbg, synthesized by liver, is the highest content of coagulation proteins in plasma and can be converted to fiber polymer (insoluble fibrin) by activated thrombin. It plays a vital role in blood coagulation, fibrinolysis, inflammatory response, wound healing, and tumorigenesis.…”

Section: Discussionmentioning

confidence: 99%

“…[1] Non-small cell lung cancer (NSCLC) accounts for the vast majority of lung cancers, mainly including lung adenocarcinoma and squamous cell carcinoma (SCC). [2–4] When diagnosed, most patients have been already in locally advanced or metastatic stages of cancer. [4,5] The blood of cancer patients often stays in hypercoagulable state, especially in the patients with advanced clinicopathological stages (CS).…”

Section: Introductionmentioning

confidence: 99%

“…[2–4] When diagnosed, most patients have been already in locally advanced or metastatic stages of cancer. [4,5] The blood of cancer patients often stays in hypercoagulable state, especially in the patients with advanced clinicopathological stages (CS). [6–8] Activation of the coagulation system and procoagulant changes have been relevant to angiogenesis, tumor invasion, cancer progression, and distant metastasis.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

The relationship of plasma fibrinogen with clinicopathological stages and tumor markers in patients with non-small cell lung cancer

Bian¹,

Shi

Qi³

et al. 2019

Medicine

View full text Add to dashboard Cite

Numerous studies have shown that the blood of cancer patients are generally in hypercoagulable statement. The aim of the present research is to study the relationships of plasma fibrinogen (Fbg) levels with clinicopathological stages (CS) and tumor markers of non-small cell lung cancer (NSCLC). Baseline information, plasma Fbg levels, CS, and expression level of tumor markers were collected from medical records retrospectively. Unitary linear regression was used to analyze the relationships between continuous variables and Fbg, and multiple linear regression was used to analyze the relationships between categorical variables and Fbg. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (Version 4) for NSCLC were adopted to evaluate CS. A total of 652 NSCLC patients were included. Compared with the females, male patients had higher mean plasma Fbg levels ( P < .001). The later the N stages ( P = .002), M stages ( P = .002), and CS ( P = .001) were, the higher the average plasma Fbg levels were. The levels of squamous cell carcinoma antigen ( P = .001), carbohydrate antigen 125 ( P = .041), and neuron-specific enolase ( P < .001) were positively correlated with plasma Fbg concentration. The plasma level of Fbg in lung adenocarcinoma patients ( P < .001) was the lowest, while that of lung squamous cell carcinoma patients ( P < .001) was the highest in NSCLC patients. The plasma Fbg concentration is related to gender, CS, and tumor markers in patients with NSCLC.

show abstract

Albumin‐to‐fibrinogen ratio as a promising biomarker to predict clinical outcome of non‐small cell lung cancer individuals

Jiang

Lin

et al. 2018

Cancer Medicine

View full text Add to dashboard Cite

Chronic inflammation is one of the critical causes to promote the initiation and metastasis of solid malignancies including lung cancer (LC). Here, we aimed to investigate the prognostic roles of albumin (Alb)‐to‐fibrinogen (Fib) ratio (AFR), Fib and Alb in LC and to establish a novel effective nomogram combined with AFR. Four hundred twelve LC patients diagnosed between February 2005 and December 2014 were recruited in this prospective study. The prognostic roles of AFR, Fib, Alb, neutrophil‐to‐lymphocyte ratio (NLR), platelet‐to‐lymphocyte ratio (PLR) and monocyte‐to‐lymphocyte ratio (MLR) were identified by X‐tile software, Kaplan–Meier curve, Cox regression model, and time‐dependent ROC. Pretreatment high circulating Fib, low AFR, and Alb were significantly associated with increased risk of death for LC patients, especially for non‐small cell lung cancer (NSCLC) patients in all stages. The area under curves (AUCs) of AFR, Fib, and NLR were higher than them within Alb and PLR for predicting the survival of NSCLC patients. Moreover, we found that clinical outcome of high AFR patient with chemo‐radiotherapy was superior to low AFR patient; overall survival rate of stage II‐III NSCLC patients undergoing chemo‐radiotherapy was significantly lower than the surgical patients with treatment of adjuvant chemo‐radiotherapy(P = 0.001) in low AFR subgroup. On the contrary, clinical outcome of the patients receiving chemo‐radiotherapy was the same to the patients undergoing surgery and adjuvant chemo‐radiotherapy (P = 0.405) in high AFR subgroup. In addition, c‐index of predicted nomogram including AFR (0.717) for NSCLC patients with treatment of chemo‐radiotherapy was higher than that without AFR (0.707). Our findings demonstrated that circulating pretreatment AFR might be a potential biomarker to predict clinical efficacy of surgical resection and adjuvant chemo‐radiotherapy and be a prognostic biomarker for NSCLC individuals.

show abstract

Cancer-related inflammation as predicting tool for treatment outcome in locally advanced and metastatic non-small cell lung cancer

Cited by 5 publications

References 38 publications

Pre-treatment systemic immune-inflammation represents a prognostic factor in patients with advanced non-small cell lung cancer

Pre-treatment systemic immune-inflammation represents a prognostic factor in patients with advanced non-small cell lung cancer

The relationship of plasma fibrinogen with clinicopathological stages and tumor markers in patients with non-small cell lung cancer

Albumin‐to‐fibrinogen ratio as a promising biomarker to predict clinical outcome of non‐small cell lung cancer individuals

Contact Info

Product

Resources

About